An important milestone
First IndiCell PhD student to complete his mid-term review, fall 2024.
“This mid-term review is an important milestone towards my doctoral thesis. It not only marks two years of long evenings, short weekends and the experience of living abroad. Above all, it marks two years of intensive learning in the field of patient-specific cell replacement therapies and contributing to new therapies for previously incurable conditions, with my very first own publications on the way. It has been a great experience to work in such a collaborative environment, expanding my knowledge in the field of regenerative medicine and all its relevant aspects: from cutting-edge research in academia, to industry commercial and production challenges, and regulatory focus on patient safety in clinical settings. It’s definitely something I’m looking forward to continuing to work on as I approach my doctoral studies and beyond.” says Fred, who is doing his PhD in the lab of Fredrik Lanner at Karolinska Institutet after the mid-term review.
